Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Cabergoline × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pituitary Neoplasms 6 Prolactinoma 5 Pituitary ACTH Hypersecretion 3 Polycystic Ovary Syndrome 2 Acromegaly 2 Recurrence 1 Prostatic Neoplasms 1 Ovarian Hyperstimulation Syndrome 1 Neuroendocrine Tumors 1 Neoplasms 1 Melanoma 1 Hyperprolactinemia 1 Heart Valve Diseases 1 Dumping Syndrome 1 Breast Neoplasms 1 Brain Neoplasms 1 Adrenocortical Hyperfunction 1 ACTH-Secreting Pituitary Adenoma 1

Interventions

Trastuzumab 520 Paclitaxel 472 Cyclophosphamide 467 Docetaxel 411 Capecitabine 348 Letrozole 309 Fulvestrant 268 Doxorubicin 245 Tamoxifen 228 Carboplatin 224 Anastrozole 197 Radiotherapy 193 exemestane 186 Epirubicin 170 Bevacizumab 166 palbociclib 149 Lapatinib 145 Vinorelbine 143 pertuzumab 141 Gemcitabine 138 pembrolizumab 136 Surveys and Questionnaires 118 Exercise 110 Magnetic Resonance Spectroscopy 109 eribulin 103 Fluorouracil 101 Albumin-Bound Paclitaxel 100 Blood Specimen Collection 96 130-nm albumin-bound paclitaxel 90 Everolimus 87

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01730729 2019-09-17

Cabergoline in Metastatic Breast Cancer

Northwestern University

Phase EARLY_PHASE1 Completed

20 enrolled 11 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡